Dash Pharmaceuticals
Natco Pharma USA is the US subsidiary of Natco Pharma Limited, established in 2022, focused on providing accessible, effective, and affordable pharmaceutical products. It aims to establish itself as a trusted pharmaceutical brand in the United States, committed to manufacturing excellence and innovation in the pharmaceutical industry. The company offers a wide range of pharmaceutical solutions across various therapeutic categories, with a strong emphasis on quality, reliability, and environmental responsibility. Natco Pharma USA operates state-of-the-art manufacturing facilities inspected by global regulatory agencies and collaborates with a network of global partners. It is dedicated to high-quality manufacturing, innovation, and serving the diverse healthcare needs of patients and healthcare professionals in the US market.
Industries
Nr. of Employees
small (1-50)
Dash Pharmaceuticals
Suite C100, 300 Interpace Parkway, Parsippany, NJ 07054 USA
Products
Diazepam Injection 10 mg / 2 ml (pre-filled syringe)
Parenteral formulation of diazepam in a pre-filled syringe; NDC 69339-136-34. Full prescribing information linked on public drug labeling resource.
Diazepam Injection 50 mg / 10 ml (vial)
Vial formulation of diazepam for parenteral use; NDC 69339-137-05.
Nitroglycerin Sublingual Tablets 0.3 mg / 0.4 mg / 0.6 mg
Sublingual tablet formulations of nitroglycerin in multiple strengths; example NDC 69339-173-01 and related pack sizes.
Ondansetron Tablets 4 mg and 8 mg
Oral tablet formulations of ondansetron in 4 mg and 8 mg strengths; NDC examples 69339-171-03 and 69339-172-03.
Testosterone Topical Solution 30 mg / 1.5 ml
Topical solution presentation of testosterone; NDC 69339-158-10.
Chlorhexidine Gluconate Oral Rinse 0.12%
Antibacterial oral rinse formulation in multiple pack sizes; NDC examples 69339-138-17 and 69339-138-19.
Diazepam Injection 10 mg / 2 ml (pre-filled syringe)
Parenteral formulation of diazepam in a pre-filled syringe; NDC 69339-136-34. Full prescribing information linked on public drug labeling resource.
Diazepam Injection 50 mg / 10 ml (vial)
Vial formulation of diazepam for parenteral use; NDC 69339-137-05.
Nitroglycerin Sublingual Tablets 0.3 mg / 0.4 mg / 0.6 mg
Sublingual tablet formulations of nitroglycerin in multiple strengths; example NDC 69339-173-01 and related pack sizes.
Ondansetron Tablets 4 mg and 8 mg
Oral tablet formulations of ondansetron in 4 mg and 8 mg strengths; NDC examples 69339-171-03 and 69339-172-03.
Testosterone Topical Solution 30 mg / 1.5 ml
Topical solution presentation of testosterone; NDC 69339-158-10.
Chlorhexidine Gluconate Oral Rinse 0.12%
Antibacterial oral rinse formulation in multiple pack sizes; NDC examples 69339-138-17 and 69339-138-19.
Services
Collaborative business models for co-development/co-ownership of ANDAs, licensing of ANDAs, authorized generic programs, and acquisition of NDA/ANDA assets to support market entry and portfolio expansion.
Collaborative business models for co-development/co-ownership of ANDAs, licensing of ANDAs, authorized generic programs, and acquisition of NDA/ANDA assets to support market entry and portfolio expansion.
Expertise Areas
- API manufacturing
- Formulation development
- Sterile injectable production
- Oral solid dose manufacturing
Key Technologies
- GMP manufacturing
- Cytotoxic API synthesis
- Oral solid dose formulation
- Sterile injectable and pre-filled syringe production
News & Updates
NATCO Pharma USA's Facility Inspection by US FDA
Our manufacturing facilities have been inspected and approved by the US Food and Drug Administration, ensuring compliance with international standards.
Expansion of API Manufacturing Capacity in Mekaguda, India
The capacity of our API facility in Mekaguda has been increased to meet growing demand.
Natco Pharma USA Launches New Generic Drug
The company has launched a new generic medication in the US market, expanding its product portfolio.
Innovations in Pharmaceutical Manufacturing at Natco
Natco's commitment to manufacturing excellence and innovation is highlighted in recent industry publications.
US FDA Inspection Approval
Our facilities have received approval from the US FDA, demonstrating our commitment to quality and compliance.
Global Regulatory Approvals for API Facilities
Our API manufacturing facilities in India have received WHO GMP, US FDA, and other international regulatory approvals.
NATCO Pharma USA's Facility Inspection by US FDA
Our manufacturing facilities have been inspected and approved by the US Food and Drug Administration, ensuring compliance with international standards.
Expansion of API Manufacturing Capacity in Mekaguda, India
The capacity of our API facility in Mekaguda has been increased to meet growing demand.
Natco Pharma USA Launches New Generic Drug
The company has launched a new generic medication in the US market, expanding its product portfolio.
Innovations in Pharmaceutical Manufacturing at Natco
Natco's commitment to manufacturing excellence and innovation is highlighted in recent industry publications.
US FDA Inspection Approval
Our facilities have received approval from the US FDA, demonstrating our commitment to quality and compliance.
Global Regulatory Approvals for API Facilities
Our API manufacturing facilities in India have received WHO GMP, US FDA, and other international regulatory approvals.